Itraconazol Aristo (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, a key step in ergosterol synthesis. By preventing ergosterol formation, the drug disrupts the integrity of the fungal cell membrane, leading to increased permeability, inhibition of growth, and ultimately fungal cell death.

The dosage of itraconazole is individualized by the prescribing healthcare professional based on the type and severity of the infection, patient weight, age, renal and hepatic function, and potential drug interactions. Only a qualified prescriber can determine the appropriate regimen.

Safety data for itraconazole in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both itraconazole and fluconazole belong to the azole class, but itraconazole has a broader spectrum against molds such as Aspergillus and dimorphic fungi, whereas fluconazole is more active against many Candida species. Itraconazole also has a higher potential for drug‑drug interactions due to stronger CYP3A4 inhibition.

Store the product at temperatures below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Do not expose the tablets or capsules to excessive heat or humidity, and keep them out of reach of children.

Itraconazol Aristo is taken orally, usually with food or a full glass of water to enhance absorption. The exact administration instructions, including whether to take it with a high‑fat meal, are provided by the prescribing clinician and should be followed precisely.

Serious adverse events include hepatotoxicity (potentially leading to liver failure), severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, exacerbation of congestive heart failure, visual disturbances, and rare cases of anaphylaxis. Patients should be monitored closely for any signs of these conditions.

Itraconazole is contraindicated in patients with known hypersensitivity to itraconazole or any azole antifungal, and in individuals with uncontrolled congestive heart failure. Caution is also advised for patients with severe hepatic impairment, as the drug is metabolized by the liver.